Incidence of febrile neutropenia during chemotherapy among patients with nonmyeloid cancer receiving filgrastim vs a filgrastim biosimilar

about

Incidence of febrile neutropenia during chemotherapy among patients with nonmyeloid cancer receiving filgrastim vs a filgrastim biosimilar

Item

http://www.wikidata.org/entity/Q58767839

description

im Januar 2018 veröffentlichter wissenschaftlicher Artikel

@de

wetenschappelijk artikel

@nl

наукова стаття, опублікована у 2018

@uk

name

Incidence of febrile neutropen ...... tim vs a filgrastim biosimilar

@en

Incidence of febrile neutropen ...... tim vs a filgrastim biosimilar

@nl

type

Item

label

Incidence of febrile neutropen ...... tim vs a filgrastim biosimilar

@en

Incidence of febrile neutropen ...... tim vs a filgrastim biosimilar

@nl

prefLabel

Incidence of febrile neutropen ...... tim vs a filgrastim biosimilar

@en

Incidence of febrile neutropen ...... tim vs a filgrastim biosimilar

@nl

P1476

Incidence of febrile neutropen ...... tim vs a filgrastim biosimilar

@en

P2093

Caitlin Elliott

http://www.w3.org/2001/XMLSchema#string

Kim Campbell

http://www.w3.org/2001/XMLSchema#string

Lee Brekke

http://www.w3.org/2001/XMLSchema#string

Lincy S Lal

http://www.w3.org/2001/XMLSchema#string

Sanjeev Balu

http://www.w3.org/2001/XMLSchema#string

Stephanie Korrer

http://www.w3.org/2001/XMLSchema#string

P2860

Understanding Equivalence and Noninferiority Testing

Over- and under-prophylaxis for chemotherapy-induced (febrile) neutropenia relative to evidence-based guidelines is associated with differences in outcomes: findings from the MONITOR-GCSF study.

Risk and consequences of chemotherapy-induced neutropenic complications in patients receiving daily filgrastim: the importance of duration of prophylaxis.

Comparative effectiveness of colony-stimulating factors for febrile neutropenia: a retrospective study.

Prophylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: where are we now?

Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries.

The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials

2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.

Pegfilgrastim prophylaxis is associated with a lower risk of hospitalization of cancer patients than filgrastim prophylaxis: a retrospective United States claims analysis of granulocyte colony-stimulating factors (G-CSF)

Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients.

P304

493-500

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/CEOR.S168298

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P50

Lee S Schwartzberg

P577

2018-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30214262

http://www.w3.org/2001/XMLSchema#string

P921

health policy

chemotherapy

P932

6126503

http://www.w3.org/2001/XMLSchema#string